267 related articles for article (PubMed ID: 30450757)
1. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study.
Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
4. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
5. Association of metabolic syndrome with prostate cancer diagnosis and aggressiveness in patients undergoing transrectal prostate biopsy.
Fragkoulis C; Glykas I; Tzelves L; Stasinopoulos K; Lazarou L; Kaoukis A; Dellis A; Stathouros G; Papadopoulos G; Ntoumas K
Arch Ital Urol Androl; 2021 Sep; 93(3):291-295. PubMed ID: 34839634
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of metabolic syndrome and prostate cancer.
Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
8. The effect of metabolic syndrome on prostate cancer final pathology.
Caliskan S; Kaba S; Özsoy E; Keleş MO; Koca O; Akyüz M; Karaman MI
J Cancer Res Ther; 2019 Mar; 15(Supplement):S47-S50. PubMed ID: 30900620
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer.
Russo GI; Cimino S; Giranio G; Regis F; Favilla V; Privitera S; Motta F; Caltabiano R; Stenzl A; Todenhöfer T; Morgia G
Urol Oncol; 2018 May; 36(5):240.e21-240.e26. PubMed ID: 29429896
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank.
Monroy-Iglesias MJ; Russell B; Crawley D; Allen NE; Travis RC; Perez-Cornago A; Van Hemelrijck M; Beckmann K
Int J Cancer; 2021 Feb; 148(4):825-834. PubMed ID: 33405276
[TBL] [Abstract][Full Text] [Related]
11. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
12. Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome.
Chen Z; Deng J; Yan Y; Li M; Chen C; Chen C; Zhao S; Song T; Liu T; Wen X; Yao Y
Horm Cancer; 2018 Aug; 9(4):278-287. PubMed ID: 29948970
[TBL] [Abstract][Full Text] [Related]
13. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
Cicione A; De Nunzio C; Tubaro A; Cantiello F; Manno S; Oliveira C; Lima E; Damiano R
BMC Cancer; 2016 Feb; 16():59. PubMed ID: 26846521
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
16. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
[TBL] [Abstract][Full Text] [Related]
17. The relationship between prostate cancer and presence of metabolic syndrome and late-onset hypogonadism.
Kayali M; Balci M; Aslan Y; Bilgin O; Guzel O; Tuncel A; Atan A
Urology; 2014 Dec; 84(6):1448-52. PubMed ID: 25281522
[TBL] [Abstract][Full Text] [Related]
18. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.
Albisinni S; De Nunzio C; Tubaro A; Barry WT; Banez LL; Freedland SJ
Urology; 2012 Jul; 80(1):162-7. PubMed ID: 22608797
[TBL] [Abstract][Full Text] [Related]
19. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.
Dell'Atti L; Galosi AB
Asian J Androl; 2018; 20(1):15-18. PubMed ID: 28695864
[TBL] [Abstract][Full Text] [Related]
20. Human C-reactive protein and the metabolic syndrome.
Devaraj S; Singh U; Jialal I
Curr Opin Lipidol; 2009 Jun; 20(3):182-9. PubMed ID: 19369869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
